Full-Time
Posted on 9/11/2025
Develops and commercializes biosimilar biologics
$115k - $175k/yr
San Carlos, CA, USA
In Person
Location specified as Redwood City, California. No mention of remote or hybrid. Company offices in multiple locations not relevant.
| , , |
Coherus BioSciences develops and sells biosimilars, which are highly similar versions of approved biologic medicines. These products are created through biotechnology to match the safety and effectiveness of the original biologics while offering lower prices. Coherus’ products are designed to provide patients and healthcare systems with more affordable access to essential biologic treatments and to offset rising healthcare costs. The company differentiates itself by focusing on high-quality biosimilars and a rigorous regulatory pathway to ensure similar efficacy and safety to the originals, enabling broader adoption among providers, hospitals, and patients. Its goal is to improve patient lives by expanding access to life-changing biologic medicines and making treatments more affordable.
Company Size
201-500
Company Stage
IPO
Headquarters
Redwood City, California
Founded
2010
Help us improve and share your feedback! Did you find this helpful?
Competitive base salary
Target bonus based on performance
stock options
Medical, dental, & vision coverage
PTO
401(k) plan
FSA
Coherus Oncology has reported strong revenue growth for 2025, with its drug LOQTORZI achieving net revenue of $40.8 million, a 113% increase from $19.1 million in 2024. Fourth-quarter revenue reached $12.4 million, marking an 11% growth over the third quarter. The company significantly improved its financial position by reducing debt by over 90%, from $480 million to $38.8 million by year-end 2025. This resulted in interest cost savings of over $15 million. The firm also cut headcount by 35% and reduced selling, general and administrative expenses to $23.6 million in Q4 from $29.6 million the previous year. Coherus ended 2025 with $172.1 million in cash and investments whilst developing two promising product candidates, Tagmokitug and casdozokitug.
Coherus Oncology has reduced its debt by approximately 90%, cutting it from $480 million to $3.7 million in senior secured debt, whilst adding $250 million to its balance sheet through biosimilar asset divestitures following its 2023 Surface Oncology acquisition. The company reported accelerating sales of LOQTORZI, its PD-1 therapy for nasopharyngeal carcinoma, with 2025 sales doubling from 2024's $19 million. Management expects quarterly sales to reach $15 million to $16 million in 2026, covering the commercial team's costs, and projects a long-term run rate of roughly $175 million annually by 2028. Coherus aims to achieve cash-flow breakeven, excluding clinical trial costs, when quarterly sales exceed $30 million. The company has scheduled clinical data readouts for two pipeline assets in 2026.
Coherus Oncology has priced an underwritten public offering of 28.6 million shares of common stock at $1.75 per share. The company expects to raise approximately $50.1 million in gross proceeds before underwriting discounts and expenses. The offering includes a 30-day option for underwriters to purchase an additional 4.29 million shares. The transaction is expected to close on 17 February 2026. Coherus plans to use the net proceeds to support commercialisation of LOQTORZI, continue clinical development of product candidates, and for working capital and general corporate purposes. The commercial-stage oncology company has an approved PD-1 inhibitor and a pipeline targeting liver, prostate, head and neck, and colorectal cancers. TD Cowen, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunners.
Coherus management to present at the 44th Annual J.P. Morgan Healthcare Conference. REDWOOD CITY, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) - Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 10:30 a.m. Pacific Time. The presentation and Q&A session will be accessible via webcast through a link posted on the Investor Events Calendar section of the Coherus website: https://investors.coherus.com/events-presentations. This webcast will be available for replay until February 13, 2026. About Coherus Oncology Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI(R)(toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, colorectal and other cancers. The Company's strategy is to grow sales of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as through its partners, driving sales multiples and synergies from proprietary combinations. Coherus' innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors, including head and neck squamous cell carcinoma, colorectal cancer, gastric cancer, and esophageal cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma. For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, please visit www.loqtorzi.com.
STORM Therapeutics Announces First Patient Dosed in Clinical Collaboration to Evaluate STC-15 in Combination with LOQTORZI® and Appointment of Atif Abbas, M.D., as Chief Medical Officer. STC-15 has demonstrated durable clinical activity and tolerability to progress into a combination study with a checkpoint inhibitor